- Clinical Interests
- Depressive disorders
- Medical Education
- MD, University of Padua - Italy
- Residency, Massachusetts General Hospital|Residency, University of Padua - Italy
- Board Certifications
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Great-West Healthcare (formally One Health Plan)
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Behavioral Health
- United Behavioral Health - MGH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology there. He completed residency training in psychiatry at Mass. General Hospital (MGH). He founded and was Director of the MGH Depression Clinical and Research Program (DCRP) from 1990 until 2014. Under Dr. Fava's direction, the DCRP became one of the most highly regarded depression programs in the country, conducting research in pharmacotherapy of resistant depression, neuroimaging, genetics, neurophysiology, neuroendocrinology, novel pharmacotherapies, alternative medicine, and psychotherapy. Dr. Fava successfully obtained funding for his program, as principal or co-principal investigator, from the NIH and industry for a total of more than $60,000,000 in the past 23 years. Since 2007, he has been Director of the MGH Clinical Trials Network and Institute, an academic CRO specialized in multicenter trials and in the use of innovative research methodologies. In 2014, Dr. Fava was selected as Director of MGH's Clinical Research Program (CRP).
Dr. Fava authored or co-authored more than 600 original articles in medical journals with international circulation. He has also edited eight books, and published more than 50 chapters and 500 abstracts. Dr. Fava is a well-known speaker, having given more than 350 presentations at national and international meetings. He is currently Director, MGH's CRP, Executive Vice Chair for the MGH Dept. of Psychiatry, Executive Director, CTNI, and Slater Family Professor of Psychiatry at Harvard Medical School.
Dr. Fava is Editor-in-Chief of MGH's
Mind, Mood & Memory newsletter. Click on the link for more information and a free trial issue.
Following the cutting of a ceremonial blue ribbon and an enthusiastic round of applause, the doors to the new MGH Translational and Clinical Research Center (TCRC) officially opened Nov. 30.
A clinical trial of an experimental drug for treatment-resistant major depression finds that modulation of the endogenous opioid system may improve the effectiveness of drugs that target the action of serotonin and related neurotransmitters.
A small clinical trial of a novel antidepressant that stimulates neurogenesis—the production of new brain cells—shows that the compound appears to be safe and may be effective against depression
Maurizio Fava, MD, executive vice chair of the Department of Psychiatry, was honored with the 2012 John T. Potts Jr., MD, Faculty Mentoring Award.
A new study will measure the ability of probiotic bacteria GanedenBC30 (Bacillus coagulans GB1-30, 6086) to help people diagnosed with irritable bowel syndrome (IBS) and major depressive disorder (MDD).
MGH Hotline 06.26.09 In General awards and honors
cites journal editorial by MGH investigator Maurizio Fava
55 Fruit Street
Boston MA, 02114-2696